SCHEMBL1721571

SCHEMBL1721571

COC(=O)c1ccccc1S(=O)(=O)Nc1cc(F)cc(Oc2cccnc2)c1

nearest known ligand 0.64

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
FFAR4 Q5NUL3 2/20 0.64
KMT2A Q03164 2/20 0.52
MEN1 O00255 1/20 0.52
MAPT P10636 1/20 0.50
ALPL P05186 4/20 0.47
SLC40A1 Q9NP59 1/20 0.45
NPC1 O15118 1/20 0.44
GAA P10253 1/20 0.44
HPGD P15428 1/20 0.44
RAB9A P51151 1/20 0.44
PTPN2 P17706 1/20 0.43
PTPN1 P18031 1/20 0.43
PTPN5 P54829 1/20 0.43
BRD4 O60885 2/20 0.42
MMP2 P08253 1/20 0.42
MMP13 P45452 1/20 0.42
SLC22A12 Q96S37 1/20 0.41
PRF1 P14222 1/20 0.41
ALDH1A1 P00352 1/20 0.41
TP53 P04637 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1721093 0.82 FFAR4 (0.67) FFAR4KMT2AMEN1ALPLNPC1
SCHEMBL1050952 0.80 MEN1 (0.66) KMT2AMEN1MAPTALPLSLC40A1
SCHEMBL1055634 0.77 MEN1 (0.65) KMT2AMEN1MAPTALPLSLC40A1
SCHEMBL12167785 0.73 MMP2 (0.67) KMT2AMEN1MAPTSLC40A1NPC1
SCHEMBL29139940 0.72 KMT2A (0.64) KMT2AMEN1NPC1GAAHPGD
SCHEMBL1957070 0.72 KMT2A (0.51) FFAR4KMT2AMEN1NPC1GAA
SCHEMBL1053050 0.71 MEN1 (0.60) KMT2AMEN1MAPTALPLSLC40A1
SCHEMBL4276324 0.71 TAAR1 (0.64) FFAR4KMT2AMEN1MAPTNPC1
SCHEMBL2741010 0.70 NPC1 (0.66) KMT2AMEN1MAPTSLC40A1NPC1
SCHEMBL4475675 0.70 TSHR (0.59) FFAR4KMT2ATDP1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2406248-B1 NOVEL ISOINDOLIN-1-ONE DERIVATIVE MSD KK (JP) 2013-12-25 EP disclosed
US-8362052-B2 Isoindolin-1-one derivative MSD K.K. (JP) 2013-01-29 US disclosed
EP-2406248-A1 NOVEL ISOINDOLIN-1-ONE DERIVATIVE MSD K.K. (JP) 2012-01-18 EP disclosed
US-20110312976-A1 NOVEL ISOINDOLIN-1-ONE DERIVATIVE MSD K.K. (JP) 2011-12-22 US disclosed
WO-2010104195-A1 NOVEL ISOINDOLIN-1-ONE DERIVATIVE BANYU PHARMACEUTICAL CO.,LTD. (JP) 2010-09-16 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110312976-A1 NOVEL ISOINDOLIN-1-ONE DERIVATIVE CBR3, OPRD1, CBR1 FFAR4 4244/4885KMT2A 2849/4885MEN1 3744/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.